Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Fitness technology MyFiziq has signed Evolt360. MyFiziq technology is intended to extend the Evolt reach to the hands of consumers at home.

Evolt is a machine based body scanning technology which is supported by health, fitness and wellness companies such as F45, Anytime Fitness, and Life Fitness Distributors.

These companies are looking to provide greater insight into the health of its members and employees.

A low-intensity electrical current is passed through the body, via the feet and hands, and it determines the difference between muscle mass, fat mass, minerals, and water.

The machines cost between $12,000-$20,000 with trained staff to run them and the scans cost between $30-$50 per person depending on the type of scan performed.

MyFiziq uses images from phone to create a realistic 3D avatar of your body which allows for customers to track changes and even buy clothing online.

Co-Founder and Chief Executive Officer of Evolt is excited to show what the future could hold.

“I am extremely confident this is the future of digital dimension, having the ability to place in in the palm of the consumer’s hand and is highly complementary to our offering and strategic decision,” he said.

There are currently more than 4,000 new orders which will begin rolling out soon.

Please find announcement attached here: https://hotcopper.com.au/data/pricesensitive/announcements/ASX/6A926641_MYQ.html

MYQ by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.